

Leicester General Hospital
Gwendolen Road
Leicester
LE5 4PW

Tel: 0116 249 0490
Fax: 0116 258 4666
Minicom: 0116 258 8188

DIRECTORATE OF RESEARCH & DEVELOPMENT

Direct Dial: (0116) 2588351
Fax No: (0116) 2584226

MHRA
PO Box 3995
345 Edinburgh Avenue
Slough
SL1 0LZ

19th January 2010

To whom it may concern

Re; Eudra CT 2007-000715-29 UHL ref no 10325

Please find enclosed end of study declarations for the above study.

Yours sincerely

Sharon Turner

Sharon Turner
R&D Administrator

Declaration of the end of trial form

NOTIFICATION OF THE END OF A CLINICAL TRIAL OF A MEDICINE FOR HUMAN USE TO THE COMPETENT AUTHORITY AND THE ETHICS COMMITTEE

For official use

Date of receipt:	Competent authority registration number: Ethics committee registration number:
------------------	---

To be filled in by the applicant

A MEMBER STATE IN WHICH THE DECLARATION IS BEING MADE: UK

B TRIAL IDENTIFICATION

B.1 EudraCT number:	2007-000715-29
B.2 Sponsor's protocol code number:	10325
B.3 Full title of the trial:	Serum and urinary strontium levels and possible interference with the measurement of other minerals in subjects treated with Strontium Ranelate (Protelos) for osteoporosis.

C APPLICANT IDENTIFICATION (please tick the appropriate box)

C.1 DECLARATION FOR THE COMPETENT AUTHORITY		<input checked="" type="checkbox"/>
C.1.1 Sponsor		<input checked="" type="checkbox"/>
C.1.2 Legal representative of the sponsor		<input checked="" type="checkbox"/>
C.1.3 Person or organisation authorised by the sponsor to make the application.		<input type="checkbox"/>
C.1.4 Complete below:		<input type="checkbox"/>
C.1.4.1 Organisation:	University Hospitals of Leicester NHS Trust	
C.1.4.2 Name of person to contact:	Carolyn Maloney	
C.1.4.3 Address:	Trust Headquarters Gwendolen House Gwendolen Road Leicester	
C.1.4.4 Telephone number:	01162584109	
C.1.4.5 Fax number:		
C.1.4.6 E-mail	carolyn.maloney@uhl-tr.nhs.uk	

C.2 DECLARATION FOR THE ETHICS COMMITTEE		<input checked="" type="checkbox"/>
C.2.1 Sponsor		<input checked="" type="checkbox"/>
C.2.2 Legal representative of the sponsor		<input checked="" type="checkbox"/>
C.2.3 Person or organisation authorised by the sponsor to make the application.		<input type="checkbox"/>
C.2.4 Investigator in charge of the application if applicable ¹ :		<input type="checkbox"/>
• Co-ordinating investigator (for multicentre trial):		<input type="checkbox"/>
• Principal investigator (for single centre trial):		<input type="checkbox"/>
C.2.5 Complete below:		
C.2.5.1 Organisation:	University Hospitals of Leicester NHS Trust	
C.2.5.2 Name:	Carolyn Maloney	
C.2.5.3 Address:	Trust Headquarters Gwendolen House Gwendolen Road Leicester	
C.2.5.4 Telephone number:	01162584109	
C.2.5.5 Fax number:		
C.2.5.6 E-mail:	carolyn.maloney@uhl-tr.nhs.uk	

¹ According to national legislation

D END OF TRIAL

D.1 Is it the end of the trial in this Member State?

yes ☒ no ☐

D.1.1 If yes, give date (YYYY/MM/DD):

D.2 Is it the end of the complete trial in all countries concerned by the trial?

yes ☒ no ☐

D.2.1 If yes, give date (YYYY/MM/DD):

D.3 Is it a premature ending of the trial?

yes ☒ no ☒

D.3.1 If yes, give date (YYYY/MM/DD):

2008/06/03

D.3.2 What is (are) the reason(s) for the premature ending?
start trial

No paperwork submitted to R&D to

D.3.2.1 Safety

yes ☐ no ☒

D.3.2.2 Lack of efficacy

yes ☐ no ☒

D.3.2.3 The trial has not commenced

yes ☒ no ☐

D.3.2.4 Other

yes ☐ no ☒

D.3.3 If yes to any of the above questions, briefly describe in an annex (free text):

D.3.3.1 The justification for premature ending of the trial:
submitted to R&D to start trial

No paperwork

D.3.3.2 Number of patients still receiving treatment at time of premature termination in the MS concerned by the declaration and their proposed management:

NA - abandoned

D.3.3.3 The consequences of early termination for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product:

NA - abandoned

E SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

E.1 I hereby confirm that/confirm on behalf of the sponsor that (delete which is not applicable):

- The above information given on this declaration is correct; and
- That a summary of the clinical trial report will be submitted to the competent authority and ethics committee concerned as soon as available and within a 1 year deadline after the end of the trial in all countries.

E.2 APPLICANT TO THE COMPETENT AUTHORITY (as stated in C.1)

☒

E.2.1 Date : 2010-01-20

E.2.2 Signature :

Carolyn Maloney

E.2.3 Print name:

Carolyn Maloney

E.3 APPLICANT TO THE ETHICS COMMITTEE (as stated in C.2) :

☒

E.3.1 Date : 2010-01-20

E.3.2 Signature :

Carolyn Maloney

E.3.3 Print name:

Carolyn Maloney